Christopher Specht Email & Phone Number

Boston, Ma, Us

Orange, Connecticut, Us

Toronto, Ca

- Built operating projections based on Filecoin fundamentals/tokenomics, for an investor audience- Strategically analyzed liquid staking protocols to determine capital efficient staking options- Conducted on- and off-chain research into cutting edge Ethereum and Filecoin network developments

Boston, Massachusetts, Us

Boston, Massachusetts, Us

Built and managed relationships with management and ownership of potential targets to convince them to accept investment. Coordinated due diligence of portfolio targets to present findings and recommendations for M33’s investment committee resulting in new companies added to the M33 pipeline.Created clinical trial software investment thesis & market map to guide sourcing efforts and enable future life sciences software investments.

New York, Ny, Us

Constructed dynamic financial models used to perform leveraged buyout, discounted cash flow, sum-of-the-parts, comparable company, precedent transaction, and pro forma combination analyses including accretion/dilution and credit impact.Evaluated strategic rationale and financial viability of mergers, acquisitions, leveraged buyouts, equity and debt offerings, and major corporate actions across all verticals within the healthcare industry.Prepared board, management, and roadshow presentations; presented analysis in client and internal committee meetings.Select Transaction Experience:Advised Windjammer Capital in $780MM Sale of Advanced Instruments | (Sole Advisor, Announced 9/28/2020)Sole analyst writing the confidential information memorandum (CIM) and marketing documents to compel interest from strategic buyers and sponsors.Developed flexible, standalone operating model from company financials as part of a comprehensive valuation.Performed detailed financial due diligence on target to gauge validity of management projections, to determine appropriate revenue growth assumptions and extent of possible synergies in an acquisition.Advised Fusion Pharmaceuticals in $213MM IPO | (Lead-Left Bookrunner; Announced 6/25/2020)Coordinated due diligence sessions and meetings with investors to market Fusion and the transaction.Created marketing materials for aforementioned investor meetings in collaboration with 3 person team.Developed valuation materials to help determine the transaction size.

New York, Ny, Us

Selected Transaction ExperienceAdvised RegenxBio in $175MM Follow-On Offering | (Lead-Left Bookrunner; Announced 8/10/2018)Aggregated broker models to form a consensus street valuation as part of a comprehensive valuation.Evaluated likelihood of FDA approval for gene therapies in company pipeline to develop probability-adjusted DCF valuation and calculate incremental risk-adjusted value impact of reaching approval milestones.Assessed risk of a hostile takeover and structural defenses of RegenxBio to withstand such attempts.

New York, Ny, Us

Banks and Broker Dealers Sales TeamIdentified and remediated customer pricing errors, saving the firm ~$90,000 per year.Shortened time needed to make weekly reports from 3-4 hours to ~25 seconds via VBA automation.